RNAi's Biggest Problem Just Got a $200 Million Bet
City Therapeutics just raised $200 million in an upsized IPO to crack RNAi's hardest problem: getting gene-silencing drugs to work outside the liver. With a team of Alnylam alumni and nearly half a billion in total funding, they're making the biggest bet yet on extrahepatic delivery.
The Liver Trap
RNA interference is one of the most elegant ideas in modern medicine. Design a tiny strand of RNA, inject it into the body, and silence the gene causing disease. Simple, right?
There's just one catch. For nearly two decades, RNAi drugs have been stuck in the liver. Getting these therapies to work in hepatocytes (liver cells) is a solved problem. Getting them to work anywhere else in the body? That's the trillion-dollar question nobody has answered yet. No extrahepatic RNAi therapy has ever been approved.
Now, a startup called City Therapeutics just raised $200 million in its IPO to prove it can break RNAi out of liver jail.
A Debut That Turned Heads
City Therapeutics started trading on the Nasdaq under the ticker CTY on October 16, selling 11.1 million shares at $18 each. The deal was originally smaller, but bankers upsized it after seeing demand. Goldman Sachs, Jefferies, Stifel, and Oppenheimer ran the books. Underwriters also secured a 30-day option to buy an additional 1.67 million shares, which could push total proceeds even higher.
In a biotech IPO market that's been picky all year, upsizing is a genuine signal. It means institutional investors weren't just willing to buy; they were fighting for allocation. That's a meaningful vote of confidence for a company that was only founded in July 2023.
The Alnylam Alumni Club
The investor enthusiasm makes more sense when you look at the roster. City Therapeutics reads like a reunion tour for Alnylam Pharmaceuticals, the company that essentially built the RNAi industry.
Executive chairman John Maraganore was Alnylam's founding CEO. Chief scientific officer Tracy Zimmermann was a senior research director there. Co-founder Mark Keating was a Vice President and Distinguished Fellow at Alnylam. CEO Andrew Orth led the U.S. commercial launch of Onpattro, the first FDA-approved RNAi drug. Co-founder of ARCH Venture Partners provided the venture backbone.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Robert Nelsen
Think of it this way: if you were going to assemble an Ocean's Eleven crew to pull off the hardest heist in RNAi, this is the team you'd draft.
The venture pedigree matches. Before the IPO, City had already raised roughly $239 million across two private rounds. The $135 million Series A in October 2024 was led by ARCH, with Fidelity, Regeneron Ventures, and others joining. A $99.5 million Series B followed in June 2026, adding Viking Global and Sofinnova. ARCH reportedly held around 35% of the company heading into the listing.
So What Exactly Are They Building?
City's pitch centers on proprietary delivery technology designed to get siRNA (small interfering RNA, the molecular "off switch") into tissues that have been unreachable: eyes, brain, fat tissue, and potentially muscle and lung.
The company has three programs moving toward or already in clinical testing:
CITY-FXI targets Factor XI to prevent blood clots. It entered a Phase 1 trial in 2026, with a Phase 2 study in knee replacement patients planned next.
CITY-RBP4 goes after a protein involved in Stargardt disease (a form of inherited blindness) and geographic atrophy. A Phase 1 trial is expected by late 2026.
CITY-TFR2 targets a protein linked to anemia in chronic disease, with a company-sponsored Phase 1/2 trial planned for early 2027.
The first program is liver-directed (Factor XI is made in the liver), but it serves as a proof-of-concept for City's next-generation siRNA chemistry. The real moonshots are the ocular and other extrahepatic candidates.
Why Getting Past the Liver Is So Hard
Imagine the liver as a massive Amazon warehouse with a perfect delivery system. Packages (siRNA molecules) arrive, get sorted, and reach the right cells efficiently. That's because scientists figured out a chemical trick called GalNAc conjugation that essentially slaps a "deliver to liver" label on each molecule.
Now imagine trying to deliver those same packages to a cabin in rural Montana with no address, no roads, and a locked gate. That's what extrahepatic delivery feels like.
The challenges stack up quickly. First, you need the drug to actually reach the right organ instead of getting vacuumed up by the liver. Then it has to enter the correct cell type. Then it has to escape from the cell's internal recycling system (endosomes) before getting destroyed. Then it has to find and load into the silencing machinery (called RISC) to actually do its job. Each step is a potential failure point, and solving all of them simultaneously in non-liver tissue remains biotech's version of threading five needles at once.
City Isn't Alone in This Race
The extrahepatic land grab is heating up fast. Arrowhead Pharmaceuticals is arguably the most aggressive competitor, with its TRiM platform targeting lung, muscle, fat, and even brain tissue via blood-brain barrier crossing constructs. Alnylam itself is pushing beyond liver with targeted lipid nanoparticles, C16 conjugates, and a 2025 collaboration with PeptiDream on peptide-siRNA conjugates for select tissues.
Novo Nordisk, which acquired Dicerna, brings enormous cardiometabolic resources to bear on renal and metabolic targets. Smaller players like Rona Therapeutics are competing in adipose-targeted RNAi specifically.
The IPO market is reflecting this renewed excitement. Just weeks before City's listing, ADARx Pharmaceuticals raised a whopping $446 million in its own RNAi IPO, pricing at the top of its range. BioPharma Dive noted it was the first RNAi biotech to price a U.S. IPO in over a decade. City followed right behind, and both deals getting done signals that investors see a real inflection point for the technology.
The $200 Million Question
City Therapeutics has the pedigree, the funding, and the platform story. What it doesn't have yet is clinical proof that its extrahepatic delivery actually works in humans. The CITY-FXI Phase 1 data will be the first real test, and while that program targets a liver-produced protein, investors will be watching the siRNA chemistry closely for signs that the platform translates.
The company now has roughly $439 million in total capital raised (pre-IPO plus IPO proceeds). That's a long runway for a clinical-stage biotech, potentially enough to generate proof-of-concept data across multiple programs.
But capital isn't the bottleneck. Biology is. Every major RNAi player has been chasing extrahepatic delivery for years, and none have cracked it at the regulatory level. City is betting that fresh chemistry, fresh thinking, and a team that already built the RNAi industry once can do it again in harder tissues.
If they're right, the $200 million will look like a bargain. If they're wrong, it joins a long list of well-funded bets on a problem that might need another decade to solve. Either way, the race to break RNAi out of the liver just got its most interesting new entrant.
Clinical & Regulatory4 min read
China Just Locked the Vault on Biotech Secrets (But Left a Window Open)
China proposed banning the export of key biotech technologies while explicitly allowing licensing, partnerships, and contract research to continue. It's a move that could reshape how every major pharma company structures its China deals.
